Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + gemcitabine + paclitaxel
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The cisplatin + gemcitabine + paclitaxel combination is a triple chemotherapy regimen that has been studied for various cancer types. This regimen works through multiple mechanisms to disrupt cancer cell division and growth. Cisplatin forms crosslinks with DNA, interfering with cell division. Gemcitabine is a nucleoside analog that inhibits DNA synthesis. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. The combination has shown effectiveness in treating advanced non-small cell lung cancer (NSCLC), germ cell tumors, and is being investigated for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
- Brand names
- GemzarTaxolPlatinol
- Other names
- cisplatin-gemcitabine-paclitaxel combination
02
Targets
DNA polymerase familyDNAMicrotubule
Beyond the preview
Go deeper on cisplatin + gemcitabine + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + gemcitabine + paclitaxel.